National indication document and aortic valve replacement landscape in the Netherlands.

IF 1.7 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Netherlands Heart Journal Pub Date : 2023-12-01 Epub Date: 2023-10-16 DOI:10.1007/s12471-023-01811-1

Rob Eerdekens, Gijs van Steenbergen, Mohamed El Farissi, Jesse Demandt, Marcel van 't Veer, Edgar Daeter, Leo Timmers, Arend de Weger, Niki Medendorp, Pim Tonino

{"title":"National indication document and aortic valve replacement landscape in the Netherlands.","authors":"Rob Eerdekens, Gijs van Steenbergen, Mohamed El Farissi, Jesse Demandt, Marcel van 't Veer, Edgar Daeter, Leo Timmers, Arend de Weger, Niki Medendorp, Pim Tonino","doi":"10.1007/s12471-023-01811-1","DOIUrl":null,"url":null,"abstract":"Introduction: Based on European guidelines, transcatheter aortic valve implementation (TAVI) could be the therapy of choice in patients with severe aortic stenosis aged ≥ 75 years. In the Netherlands, there has been a debate between healthcare providers and the National Health Care Institute regarding reimbursement for TAVI, which resulted in an indication document that defines TAVI patients who are eligible for reimbursement. This document has been effective since 1 January 2021.Methods: We extracted data from the Netherlands Heart Registry for patients who underwent biological surgical aortic valve replacement (SAVR) or TAVI in the Netherlands from 2018 through 2021. We compared baseline characteristics and variables from the indication document for the subsequent years and age groups. We also analysed the annual SAVR/TAVI ratio.Results: The total number of patients treated with SAVR or TAVI was constant in 2018-2021. Baseline characteristics of patients treated with TAVI did not differ throughout the years. The SAVR/TAVI ratio shifted towards a higher percentage of TAVI from 2018 to 2019. From 2019 to 2020, the TAVI percentage was constant. Since the implementation of the indication document (in 2021), a change in the SAVR/TAVI ratio was not found either.Conclusion: Since the implementation of the national indication document for AVR in 2021, no major effect was seen for the SAVR versus TAVI landscape in the Netherlands.","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":"473-478"},"PeriodicalIF":1.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667164/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Netherlands Heart Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12471-023-01811-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Based on European guidelines, transcatheter aortic valve implementation (TAVI) could be the therapy of choice in patients with severe aortic stenosis aged ≥ 75 years. In the Netherlands, there has been a debate between healthcare providers and the National Health Care Institute regarding reimbursement for TAVI, which resulted in an indication document that defines TAVI patients who are eligible for reimbursement. This document has been effective since 1 January 2021.

Methods: We extracted data from the Netherlands Heart Registry for patients who underwent biological surgical aortic valve replacement (SAVR) or TAVI in the Netherlands from 2018 through 2021. We compared baseline characteristics and variables from the indication document for the subsequent years and age groups. We also analysed the annual SAVR/TAVI ratio.

Results: The total number of patients treated with SAVR or TAVI was constant in 2018-2021. Baseline characteristics of patients treated with TAVI did not differ throughout the years. The SAVR/TAVI ratio shifted towards a higher percentage of TAVI from 2018 to 2019. From 2019 to 2020, the TAVI percentage was constant. Since the implementation of the indication document (in 2021), a change in the SAVR/TAVI ratio was not found either.

Conclusion: Since the implementation of the national indication document for AVR in 2021, no major effect was seen for the SAVR versus TAVI landscape in the Netherlands.

Abstract Image

查看原文本刊更多论文

荷兰的国家适应症文件和主动脉瓣置换情况。

引言：根据欧洲指南，经导管主动脉瓣置换术（TAVI）可能是年龄≥50岁的严重主动脉瓣狭窄患者的首选治疗方法 75年。在荷兰，医疗保健提供者和国家卫生保健研究所就TAVI的报销问题进行了辩论，最终形成了一份适应症文件，定义了有资格报销的TAVI患者。本文件自2021年1月1日起生效。方法：我们从荷兰心脏登记处提取了2018年至2021年在荷兰接受生物外科主动脉瓣置换术（SAVR）或TAVI的患者的数据。我们比较了适应症文件中随后年份和年龄组的基线特征和变量。我们还分析了每年的SAVR/TAVI比率。结果：2018-2021年，接受SAVR或TAVI治疗的患者总数保持不变。接受TAVI治疗的患者的基线特征多年来没有差异。从2018年到2019年，SAVR/TAVI比率向TAVI的更高百分比转变。从2019年到2020年，TAVI的百分比保持不变。自指示文件实施以来（2021年），SAVR/TAVI比率也没有变化。结论：自2021年实施AVR国家适应症文件以来，荷兰的SAVR与TAVI景观没有出现重大影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Netherlands Heart Journal CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

4.70

自引率

5.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The scope of the Netherlands Heart Journal is to contribute to the national and international literature by publishing scientific papers in the field of cardiovascular medicine. It also provides a platform for Continuing Medical Education for cardiologists and those in training for the speciality of cardiology in the Netherlands. The Netherlands Heart Journal is made available to cardiologists, cardiologists in training, cardiopulmonary surgeons, cardiopulmonary surgeons in training, internists and paediatric cardiologists. The journal is the official journal of the Netherlands Society of Cardiology.